What is Sinopia Biosciences?
Sinopia Biosciences operates at the intersection of biotechnology and neurology, specifically targeting the development of novel therapeutic solutions for Parkinson's disease. Based in San Diego, California, the company functions as a research-intensive organization dedicated to altering the progression of neurodegenerative conditions. By focusing on innovative R&D, Sinopia Biosciences aims to provide healthcare providers and clinical organizations with advanced tools to improve patient outcomes. Their business model relies on a combination of grant-funded research and private equity investment, allowing them to maintain a rigorous focus on scientific discovery while building a sustainable framework for future clinical trials and potential commercial partnerships.
How much funding has Sinopia Biosciences raised?
Sinopia Biosciences has raised a total of $8.2M across 4 funding rounds:
Debt
$82K
Other Financing Round
$2M
Grant
$3.3M
Private Equity
$2.8M
Debt (2021): $82K with participation from PPP
Other Financing Round (2023): $2M led by The Michael J. Fox Foundation for Parkinson’s Research
Grant (2023): $3.3M supported by National Institute of Neurological Disorders and Stroke
Private Equity (2026): $2.8M, investors not publicly disclosed
Key Investors in Sinopia Biosciences
National Institute of Neurological Disorders and Stroke
A U.S. government organization dedicated to advancing research and health related to brain and nervous system disorders, providing critical support for neurological innovation.
The Michael J. Fox Foundation for Parkinson’s Research
A leading non-profit organization focused on accelerating scientific research and drug development to find a cure for Parkinson's disease.
Undisclosed Investor
Undisclosed investor participating in the funding round to support the advancement of neurodegenerative therapeutic research.
What's next for Sinopia Biosciences?
With the successful closure of this latest financing round, Sinopia Biosciences is expected to prioritize the expansion of its clinical development programs. The strategic allocation of these funds will likely focus on scaling internal research capabilities and fostering collaborative efforts with key stakeholders in the neurological health sector. As the company transitions into this next phase of growth, the focus will remain on validating its therapeutic candidates through robust clinical data. Investors and industry observers will be monitoring the firm's ability to translate this capital into tangible progress within the Parkinson's research landscape, potentially setting the stage for future licensing agreements or strategic acquisitions as the pipeline matures.
See full Sinopia Biosciences company page
